SLC5A2 and hydrops fetalis: Given that the effects of SGLT2 inhibitors on erythropoietic and volume status seem largely to mediate their cardiovascular benefits, some recent clinical studies showed that treatment with SGLT2 inhibitors reduced estimated fluid volume parameters in patients with type 2 diabetes [14] or HF with reduced ejection fraction [15].